Andromeda Metals Limited (ASX:ADN) has issued 31,290,502 unquoted options to three members of its key management personnel on 20 November 2026, following shareholder approval granted at the company's Annual General Meeting on 19 November 2026.
Key Points
- 31,290,502 zero exercise price options (ASX security code: ADNAA) were issued on 20 November 2026 in lieu of director fees.
- The options were issued to three key management personnel: Sue-Ann Higgins (5,391,216), Miguel Galindo (12,949,643), and Jean-Dominique Sorel (12,949,643).
- Shareholder approval for the issue was obtained at the AGM held on 19 November 2026.
- Following the issue, total unquoted ADNAA securities on issue stand at 56,084,620.
Option Issue Details and Security Classification
The 31,290,502 options issued carry the ASX security code ADNAA and are described as options expiring on various dates at various prices. The securities are unquoted and are not intended to be quoted on ASX. According to the filing, the options were issued under an employee incentive scheme as zero exercise price options in lieu of director fees. The securities rank equally in all respects from their issue date with the existing issued securities in the same class, as disclosed in the Appendix 3G filing lodged with ASX on 20 November 2026.
Allocation Across Key Management Personnel
The filing identifies three key management personnel as recipients of the newly issued options. Sue-Ann Higgins received 5,391,216 options, registered in her own name. Miguel Galindo received 12,949,643 options, also registered in his own name. Jean-Dominique Sorel received the remaining 12,949,643 options, likewise registered personally. The filing states that the issue was made with the approval of shareholders at the AGM held on 19 November 2026, and that security holder approval was obtained under Listing Rule 7.1.
Securities on Issue Following the Transaction
Following the issue, Andromeda Metals' total unquoted securities include 56,084,620 ADNAA options expiring on various dates at various prices, 35,612,144 ADNAC options expiring 2 December 2027 at nil exercise price, and 21,461,600 ADNAB performance rights. The company's quoted securities comprise 5,141,840,313 ordinary fully paid shares (ADN), 293,461,554 ADNO options expiring 2 July 2027, 338,378,131 ADNOC options expiring 30 September 2027, and 493,445,823 ADNOD options expiring 11 December 2027, as reported in the filing.



Please wait processing your request...